Sunitinib-Induced Hemoglobin Changes Are Related to the Dosing Schedule

Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands.
Journal of Clinical Oncology (Impact Factor: 18.43). 03/2009; 27(8):1339-40; author reply 1340-2. DOI: 10.1200/JCO.2008.20.6151
Source: PubMed

Full-text preview

Available from:
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The envelope constrained (EC) filtering problem is concerned with the design of a filter with minimum gain to white input noise and with a response to a given signal that fits into a prescribed envelope. Using the discrete-time orthonormal Laguerre network, the EC filtering problem is posed as a quadratic programming (QP) problem with affine inequality constraints. An iterative algorithm for solving this QP problem is proposed which serves as a basis for the derivation of adaptive algorithms for applications where the parameters of the underlying signal model are either not known or varying with time.
    Proceedings - ICASSP, IEEE International Conference on Acoustics, Speech and Signal Processing 01/1996; 3:1363-1366. DOI:10.1109/ICASSP.1996.543680
  • [Show abstract] [Hide abstract]
    ABSTRACT: We retrospectively analyzed whether increased hemoglobin is a surrogate biomarker of efficacy for vascular endothelial growth factor (VEGF) inhibitors in advanced renal cell carcinoma (RCC) patients. Twelve patients were identified who had received bevacizumab alone or as combination therapy. Eleven patients experienced a rise in hemoglobin. Median change was 1.6 g/dL (0-4.0). Degree of peak increase correlated with longer progression-free survival (PFS) in metastatic patients: increase of < 15% yielded a 3.1-month median PFS compared to 8.2 months with rises > 15%. This study identifies increased hemoglobin as a possible consequence of VEGF inhibitors. The correlation with longer PFS suggests that rise in hemoglobin may be a surrogate biomarker of efficacy.
    Cancer Investigation 07/2009; 27(8):851-6. DOI:10.1080/07357900902744528 · 2.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Multiple molecular, cellular, micro-environmental and systemic causes of anticancer drug resistance have been identified during the last 25 years. At the same time, genome-wide analysis of human tumor tissues has made it possible in principle to assess the expression of critical genes or mutations that determine the response of an individual patient's tumor to drug treatment. Why then do we, with a few exceptions, such as mutation analysis of the EGFR to guide the use of EGFR inhibitors, have no predictive tests to assess a patient's drug sensitivity profile. The problem urges the more with the expanding choice of drugs, which may be beneficial for a fraction of patients only. In this review we discuss recent studies and insights on mechanisms of anticancer drug resistance and try to answer the question: do we understand why a patient responds or fails to respond to therapy? We focus on doxorubicin as example of a classical cytotoxic, DNA damaging agent and on sunitinib, as example of the new generation of (receptor) tyrosine kinase-targeted agents. For both drugs, classical tumor cell autonomous resistance mechanisms, such as drug efflux transporters and mutations in the tumor cell's survival signaling pathways, as well as micro-environment-related resistance mechanisms, such as changes in tumor stromal cell composition, matrix proteins, vascularity, oxygenation and energy metabolism may play a role. Novel agents that target specific mutations in the tumor cell's damage repair (e.g. PARP inhibitors) or that target tumor survival pathways, such as Akt inhibitors, glycolysis inhibitors or mTOR inhibitors, are of high interest. In order to increase the therapeutic index of treatments, fine-tuned synergistic combinations of new and/or classical cytotoxic agents will be designed. More quantitative assessment of potential resistance mechanisms in real tumors and in real time, such as by kinase profiling methodology, will be developed to allow more precise prediction of the optimal drug combination to treat each patient.
    Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy 08/2009; 12(4-5):114-26. DOI:10.1016/j.drup.2009.07.001 · 9.12 Impact Factor
Show more